Trial Profile
Phase I-II study of liposomal doxorubicin (Myocet), docetaxel and trastuzumab as first-line treatment of patients with HER-2 [human epidermal growth receptor 2]/Neu positive metastatic breast cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Docetaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Zenus Pharma
- 27 Jul 2006 New trial record.